Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.43 |
| ▸ | RBP4 | P02753 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371252 | 1.00 | HTR2C (0.44) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5370297 | 0.94 | HTR2C (0.42) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14559987 | 0.94 | HTR2C (0.42) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5368296 | 0.83 | KDM1A (0.46) | MEN1KMT2ALMNA | |
| SCHEMBL5425895 | 0.79 | SCD (0.45) | RBP4KDM4ELMNAMAPTNPSR1 | |
| SCHEMBL2817663 | 0.79 | EPHX2 (0.55) | RBP4KDM4ELMNAMAPTNPSR1 | |
| SCHEMBL5425887 | 0.79 | SCD (0.45) | RBP4KDM4ELMNAMAPTNPSR1 | |
| SCHEMBL2817662 | 0.79 | EPHX2 (0.55) | RBP4KDM4ELMNAMAPTNPSR1 | |
| SCHEMBL2274616 | 0.74 | MEN1 (0.60) | RBP4MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL6786475 | 0.73 | MEN1 (0.66) | HTR2CRBP4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1370558-B1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| EP-1370558-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002059117-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | MC1R, MC4R, MC5R | HTR2C 114/4885HTR1A 86/4885SLC6A2 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.